Global Idiopathic Pulmonary Fibrosis 2016-2020 - Increased Use of Off-Label and Alternative Therapies is a Market Challenge - Research and Markets

DUBLIN, May 23, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis 2016-2020" report to their offering.

The analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis. The report also includes a discussion of the key vendors operating in this market.

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

An emerging market trend is the rise in patient assistance programs. Vendors in the market provide co-pay assistance to people who purchase the indicated medications for idiopathic pulmonary fibrosis. For instance, Roche has a co-pay assistance program to provide financial assistance to patients who purchase Esbriet. According to the Esbriet Co-pay Card Program, an eligible patient receives a 12-month prescription free of cost, attaining a maximum benefit of $24,000 during this period. The company also provides Esbriet Access Solutions that provide co-pay cards, assistance in getting drugs, and provide healthcare coverage to patients.

According to the report, a possible growth driver is the unmet medical needs of many patients. Due to the unknown disease etiology, there is no specific cure for idiopathic pulmonary fibrosis. Therapies that target the exact cause of the disease cannot be developed owing to the idiopathic nature of the disease. Even the drugs marketed for the symptomatic treatment of the disease present different effects such as upper respiratory tract infections, liver problems, nausea and vomiting, diarrhea, headache, heartburn, weight loss, and high blood pressure. This results in decreased patient compliance, creating an unmet need in the market. Pharmaceutical companies and researchers are interested in developing a drug that provides a complete cure for the disease, with minimal side effects.

Further, the report states that one challenge that could market growth is the lack of proper diagnosis of this condition.

Key vendors

- Baxter International

- Boehringer Ingelheim

- F.Hoffmann-La Roche

- Prometheus Laboratories

Other prominent vendors

- Afferent Pharmaceuticals

- Amgen

- Biogen

- Bristol-Myers Squibb

- Cipla

- FibroGen

- Gilead Sciences

- GlaxoSmithKline

- GNI Group

- Horizon Pharma

- ImmuneWorks

- MediciNova

- MedImmune (subsidiary of AstraZeneca)

- Novartis

- Pfizer

- Promedior

- ProMetic Life Sciences

- Sanofi

- Shionogi

- Zai Lab

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

- Understanding the disease

- Pathogenesis

- Signs and symptoms

- Diagnosis

- Management

- Epidemiology

PART 06: Pipeline analysis

- Lebrikizumab

- Tipelukast

- Tralokinumab

- FG-3019

- Simtuzumab

- BMS-986020

- AF-219

- SAR156597

- BG00011

- PRM-151

- PBI-4050

PART 07: Market landscape

- Market overview

- Market size and forecast

- Five forces analysis

PART 08: Market segmentation by ROA

- Oral

- Parenteral

PART 09: Market segmentation by drug class

- Systemic corticosteroids

- Immunosuppressants

- Tyrosine kinase inhibitors

- Anti-fibrotic agents

PART 10: Geographical segmentation

- Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020

- Idiopathic pulmonary fibrosis market in Americas

- Idiopathic pulmonary fibrosis market in EMEA

- Idiopathic pulmonary fibrosis market in APAC

PART 11: Market drivers

- Special regulatory designations for pipeline candidates

- Growth in patient population

- Unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges

- Unknown disease etiology

- Lack of proper diagnosis

- Increased use of off-label and alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

- Patient assistance programs

- Increase in M&A

- Rise in public awareness

PART 16: Vendor landscape

- Competitive scenario

- Market share analysis 2015

- Baxter International

- Boehringer Ingelheim

- F Hoffmann-La Roche

- Prometheus Laboratories

- Other prominent vendors

PART 17: Appendix

For more information visit http://www.researchandmarkets.com/research/g3bpxf/global_idiopathic

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com